封面
市場調查報告書
商品編碼
2170797

潛伏性結核感染檢測市場:全球市場預測,2026-2032年

Latent Tuberculosis Infection Detection Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,潛伏性結核感染檢測市場規模將成長至 23.1 億美元,複合年成長率為 6.49%。

主要市場統計數據
基準年 2025 14.8億美元
預計年份:2026年 15.8億美元
預測年份 2032 23.1億美元
複合年成長率 (%) 6.49%

潛伏性結核感染的檢測:概述

潛伏性結核感染(LTBI)的檢測旨在識別已感染結核分枝桿菌但尚未發展為活動性結核病的個體。主要的診斷方法是結核菌素皮膚試驗(TST)和干擾素釋放檢測法(IGRA),必要時輔以臨床評估和活動性結核病的診斷檢測。正確識別的LTBI在結核病預防中發揮核心作用,因為治療可以抑制其發展為活動性結核病,尤其適用於近期接觸過結核病或具有高風險臨床風險的人。

篩檢正朝著基於風險的定向檢測方向發展。

目前的趨勢是從廣泛、低檢出率的篩檢轉向針對已確診暴露人群、近期從高感染地區遷徙而來的人員、免疫功能低下者、有醫療機構或集體生活環境暴露史者以及其他具有已知風險因素的人群進行靶向檢測。雖然在接種卡介苗後結核菌素皮膚試驗(TST)特異性可能降低的情況下,干擾素γ釋放試驗(IGRA)的使用正在增加,但在檢測能力、成本或人力資源有限而難以進行血液檢測的情況下,TST仍然發揮著至關重要的作用。加強檢測、確診和預防性治療之間的協調與選擇初始檢測方法同等重要。

人工智慧可以增強工作流程,而不是取代診斷。

人工智慧 (AI) 可以透過優先確定篩檢目標、識別漏診病例、改進用於排除活動性疾病的影像學檢查觀察的解讀以及協助醫療系統內檢測能力的分配來支持潛伏性結核感染 (LTBI) 計畫。其價值取決於具有代表性的訓練資料、透明的檢驗、隱私保護以及與臨床工作流程的整合。人工智慧本身無法確診 LTBI;演算法輸出結果除了需要微生物學、放射學和流行病學證據外,還需要合格專業人員的臨床審查。

區域優先事項反映了感染率和醫療系統應對能力的差異。

在北美,篩檢通常著重於密切接觸者、來自高發生率地區的移民、接受免疫抑制治療的人群以及特定職業群。在拉丁美洲,家庭密切接觸者追蹤與改善檢測和預防性治療的可近性相結合。在歐洲,流行病學情況因國家而異,移民、密切接觸者和弱勢群體仍然是優先考慮的對象。在中東和非洲,需要加強密切接觸者追蹤、愛滋病毒和免疫抑制服務以及基層醫療的整合。在亞太地區,既存在高發生地區,也存在低發病率的先進項目,因此分散式服務取得、品質保證和基於風險的篩檢尤為重要。

多邊組織可以協調標準、採購和後續工作。

東協成員國可受益於在不同的醫療保健系統、移民健康和檢查室品管方面採用可互通的方法進行接觸者追蹤。金磚國家有機會協調在龐大且多元化的人群中進行調查、獲取診斷和累積實施經驗。歐盟可以加強通用指南、跨境衛生連續性和監測互通性。七國集團成員國可以支持證據產生、加強檢測系統和確保公平取得。海灣合作理事會國家可以專注於高流動性勞動力和移民的篩檢和衛生連續性,而北約成員國可以加強軍事相關人員和作戰人員的準備工作和標準化方法。

必須根據每個國家的具體情況制定相應的檢測途徑。

澳洲、加拿大、法國、德國、義大利、英國、英國和美國通常依賴基於風險的策略,以接觸者追蹤、為移民和難民提供醫療保健服務以及在開始某些免疫抑制療法之前篩檢基礎。巴西、印度、中國、印尼、墨西哥、俄羅斯和韓國必須在滿足其巨大的結核病控制需求的同時,兼顧檢測的可及性、卡介苗接種的普及以及區域差異。日本將成熟的公共衛生基礎設施與針對接觸者和臨床易感族群的篩檢結合。在上述所有國家,最有效的途徑是將結核菌素皮膚試驗(TST)或γ-干擾素釋放試驗(IGRA)陽性結果與及時排除活動性結核病、制定預防性治療方案、支持患者堅持用藥以及監測治療效果聯繫起來。

行業領導者應將檢測與全面的護理路徑聯繫起來。

領導者應優先考慮準確且易於取得的檢測,並設計涵蓋整個診療流程的服務,而不僅僅是檢測數量。這包括明確的基於風險的合格標準、可靠的檢體運輸、內部品管、快速的結果溝通、臨床決策支援以及轉診途徑。與公共衛生計畫合作可以改善接觸者追蹤,並擴大對服務不足人口的支持。各機構還應衡量無效或不確定檢測結果、臨床評估所需時間、預防保健的啟動和完成情況、獲取服務的公平性以及安全性結果。只有在有證據表明存在管治、人工監督以及在目標人群中已證實有效的績效時,才能實施數位工具和人工智慧。

調查方法:基於證據的檢測實踐整合

本執行摘要整合了用於檢測潛伏性結核感染 (LTBI) 的既定臨床和公共衛生原則,包括結核菌素皮膚試驗 (TST) 和干擾素γ釋放試驗 (IGRA) 的作用、基於風險的篩檢、排除活動性結核病、接觸者追蹤以及預防保健的協調。區域分析從所要求的區域、群體和國家觀點闡述了實施重點,而未賦予具體的市場價值。結論是基於已證實的流行病學和醫療保健系統差異,避免了未經證實的估計值、預測、公司歸因或市場佔有率聲明。

有效的潛伏性結核感染檢測需要整合和公正。

潛伏性結核感染(LTBI)的檢測在以下情況下最為有效:針對高風險族群進行檢測,結合臨床情況解讀檢測結果,並迅速與活動性結核病的評估和預防性治療相結合。儘管由於地區和國家差異,單一的運作模式並不適用,但通用的優先事項依然存在:可靠的診斷、訓練有素的工作人員、公平的獲取途徑、高品質的數據以及持續的追蹤。人工智慧(AI)有助於改善協調和優先排序,但負責任的實施需要檢驗和臨床課責。最佳方案會將檢測置於結核病綜合預防流程中不可或缺的一部分。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章:潛伏性結核感染檢測市場:依檢測類型分類

  • 結核菌素皮膚試驗(TST)
  • 干擾素-γ釋放試驗(IGRA)
    • T-SPOT.TB
    • QuantiFERON-TB Gold(QFT)

第8章:潛伏性結核感染檢測市場:依產品/服務分類

  • 軟體和服務
  • 試劑和耗材
  • 裝置
  • 檢測和試劑盒

第9章:潛伏性結核感染檢測市場:依應用領域分類

  • 愛滋病毒感染者
  • 與肺結核患者共同生活的家庭成員

第10章:潛伏性結核感染檢測市場:依最終用戶分類

  • 公共衛生機構和政府機構
  • 醫院
  • 診斷檢查室
  • 診所
  • 學術和研究機構

第11章:潛伏性結核感染檢測市場:依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章:潛伏性結核感染檢測市場:依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章:潛伏性結核感染檢測市場:依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 澳洲
  • 巴西
  • 義大利
  • 墨西哥
  • 韓國
  • 俄羅斯
  • 西班牙

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第15章:公司簡介

  • Abbott Laboratories
  • AID Autoimmun Diagnostika GmbH
  • ARKRAY, Inc.
  • Becton, Dickinson and Company(BD)
  • Beijing Wantai Biopharmaceutical Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bioneovan Co., Ltd.
  • Biopanda Reagents Ltd.
  • Boditech Med Inc.
  • InBios International, Inc.
  • Liofilchem Srl
  • Lionex GmbH
  • Mylab Discovery Solutions Pvt. Ltd.
  • Omega Diagnostics Group PLC
  • QIAGEN NV
  • Revvity, Inc.
  • Sanofi SA
  • SD Biosensor, Inc.
  • Serum Institute of India Pvt. Ltd
  • Thermo Fisher Scientific Inc.

第16章 主要專家

Product Code: MRR-1CF12C86008C

The Latent Tuberculosis Infection Detection Market is projected to grow by USD 2.31 billion at a CAGR of 6.49% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.48 billion
Estimated Year [2026] USD 1.58 billion
Forecast Year [2032] USD 2.31 billion
CAGR (%) 6.49%

Latent Tuberculosis Infection Detection: Executive Overview

Latent tuberculosis infection (LTBI) detection identifies people infected with Mycobacterium tuberculosis who do not have active tuberculosis disease. The principal tools are tuberculin skin testing (TST) and interferon-gamma release assays (IGRAs), supported by clinical assessment and evaluation for active disease when indicated. Detection is central to tuberculosis prevention because treatment of appropriately identified LTBI can reduce progression to active disease, particularly among people with recent exposure or elevated clinical risk.

Screening Is Shifting Toward Risk-Based, Targeted Detection

The landscape is moving from broad, low-yield screening toward targeted testing of people with documented exposure, recent migration from high-transmission settings, immunosuppression, healthcare or congregate-setting exposure, and other recognized risk factors. IGRAs are increasingly used where BCG vaccination may reduce the specificity of TST, while TST remains important where laboratory infrastructure, cost, or workforce capacity constrain blood-based testing. Better linkage between testing, confirmatory evaluation, and preventive treatment is becoming as important as the initial test choice.

Artificial Intelligence Can Strengthen Workflow Without Replacing Diagnosis

Artificial intelligence can support LTBI programs by prioritizing people for screening, identifying missed follow-up, improving interpretation of radiographic findings used to exclude active disease, and helping health systems allocate testing capacity. Its value depends on representative training data, transparent validation, privacy safeguards, and integration with clinical workflows. AI cannot by itself establish LTBI, and algorithmic outputs require qualified clinical review alongside microbiological, radiological, and epidemiological evidence.

Regional Priorities Reflect Differences in Transmission and Health-System Capacity

North America generally emphasizes targeted screening among contacts, immigrants from high-burden settings, people receiving immunosuppressive therapies, and selected occupational groups. Latin America combines household-contact investigation with efforts to improve access to testing and preventive treatment. Europe faces varied epidemiology across countries and continues to prioritize migrants, contacts, and vulnerable populations. The Middle East and Africa require stronger integration of contact investigation, HIV and immunosuppression services, and primary care. Asia-Pacific contains both high-burden settings and advanced low-incidence programs, making decentralized access, quality assurance, and risk-based screening especially important.

Multilateral Groups Can Align Standards, Procurement, and Follow-Up

ASEAN members can benefit from interoperable approaches to contact tracing, migrant health, and laboratory quality across diverse health systems. BRICS countries have an opportunity to coordinate research, diagnostics access, and implementation experience across large and varied populations. The European Union can reinforce common guidance, cross-border continuity of care, and surveillance interoperability. G7 members can support evidence generation, laboratory strengthening, and equitable access. GCC countries can focus on screening and continuity of care for mobile workforces and migrants, while NATO members can strengthen preparedness and standardized approaches for military and operational populations.

Country Contexts Require Tailored Detection Pathways

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States generally rely on risk-based strategies supported by contact investigations, immigrant and refugee health services, and screening before selected immunosuppressive treatments. Brazil, India, China, Indonesia, Mexico, Russia, and South Korea must balance substantial tuberculosis-control needs with differing laboratory access, BCG practices, and regional variation. Japan combines mature public-health infrastructure with targeted screening of contacts and clinically vulnerable groups. Across all listed countries, the most effective pathway connects a positive TST or IGRA with timely exclusion of active disease, preventive-treatment decisions, adherence support, and outcome monitoring.

Industry Leaders Should Connect Testing With Complete Care Pathways

Leaders should prioritize accurate, accessible tests and design services around the full cascade of care rather than test volume alone. This includes clear risk-based eligibility criteria, dependable specimen transport, internal quality controls, rapid result communication, clinical decision support, and referral pathways for preventive treatment. Partnerships with public-health programs can improve contact investigation and reach underserved populations. Organizations should also measure invalid or indeterminate results, time to clinical evaluation, preventive-treatment initiation and completion, equity of access, and safety outcomes. Digital tools and AI should be deployed only with governance, human oversight, and evidence of performance in the populations served.

Methodology: Evidence-Based Synthesis of Detection Practice

This executive summary synthesizes established clinical and public-health principles for LTBI detection, including the roles of TST and IGRA, risk-based screening, exclusion of active tuberculosis, contact investigation, and preventive-treatment linkage. The geographic analysis uses the requested regional, group, and country lenses to describe implementation priorities without assigning numerical market values. Conclusions are framed around documented epidemiological and health-system differences, while avoiding unsupported estimates, forecasts, company attribution, or market-share claims.

Effective LTBI Detection Depends on Integration and Equity

LTBI detection is most effective when testing is targeted to meaningful risk, interpreted in clinical context, and connected rapidly to active-disease evaluation and preventive treatment. Regional and country differences make a single operational model unsuitable, but common priorities remain: reliable diagnostics, trained staff, equitable access, high-quality data, and sustained follow-up. Artificial intelligence may improve coordination and prioritization, yet responsible implementation requires validation and clinical accountability. The strongest programs will treat detection as one component of an integrated tuberculosis-prevention pathway.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Latent Tuberculosis Infection Detection Market, by Test Type

  • 7.1. Introduction
  • 7.2. Tuberculin Skin Test (TST)
  • 7.3. Interferon-Gamma Release Assays (IGRAs)
    • 7.3.1. T-SPOT.TB
    • 7.3.2. QuantiFERON-TB Gold (QFT)

8. Latent Tuberculosis Infection Detection Market, by Offering

  • 8.1. Introduction
  • 8.2. Software & Services
  • 8.3. Reagents & Consumables
  • 8.4. Instruments
  • 8.5. Assays & Kits

9. Latent Tuberculosis Infection Detection Market, by Application

  • 9.1. Introduction
  • 9.2. People Living with HIV
  • 9.3. Household Contacts with Pulmonary TB

10. Latent Tuberculosis Infection Detection Market, by End User

  • 10.1. Introduction
  • 10.2. Public Health Agencies & Government Bodies
  • 10.3. Hospitals
  • 10.4. Diagnostic Laboratories
  • 10.5. Clinics
  • 10.6. Academic & Research Institutions

11. Latent Tuberculosis Infection Detection Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. Europe
  • 11.4. North America
  • 11.5. Latin America
  • 11.6. Africa
  • 11.7. Middle East

12. Latent Tuberculosis Infection Detection Market, by Group

  • 12.1. Introduction
  • 12.2. NATO
  • 12.3. G7
  • 12.4. BRICS
  • 12.5. European Union
  • 12.6. ASEAN
  • 12.7. GCC

13. Latent Tuberculosis Infection Detection Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. China
  • 13.4. Germany
  • 13.5. Japan
  • 13.6. India
  • 13.7. United Kingdom
  • 13.8. France
  • 13.9. Canada
  • 13.10. Australia
  • 13.11. Brazil
  • 13.12. Italy
  • 13.13. Mexico
  • 13.14. South Korea
  • 13.15. Russia
  • 13.16. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AID Autoimmun Diagnostika GmbH
  • 15.3. ARKRAY, Inc.
  • 15.4. Becton, Dickinson and Company (BD)
  • 15.5. Beijing Wantai Biopharmaceutical Co., Ltd.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. bioMerieux S.A.
  • 15.8. Bioneovan Co., Ltd.
  • 15.9. Biopanda Reagents Ltd.
  • 15.10. Boditech Med Inc.
  • 15.11. InBios International, Inc.
  • 15.12. Liofilchem S.r.l.
  • 15.13. Lionex GmbH
  • 15.14. Mylab Discovery Solutions Pvt. Ltd.
  • 15.15. Omega Diagnostics Group PLC
  • 15.16. QIAGEN N.V.
  • 15.17. Revvity, Inc.
  • 15.18. Sanofi S.A.
  • 15.19. SD Biosensor, Inc.
  • 15.20. Serum Institute of India Pvt. Ltd
  • 15.21. Thermo Fisher Scientific Inc.

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Latent Tuberculosis Infection Detection Market, Years Considered for the Study
  • FIGURE 2. Global Latent Tuberculosis Infection Detection Market, Research Design
  • FIGURE 3. Global Latent Tuberculosis Infection Detection Market, Research Framework
  • FIGURE 4. Global Latent Tuberculosis Infection Detection Market, Data Triangulation
  • FIGURE 5. Global Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Latent Tuberculosis Infection Detection Market Size, by Test Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Latent Tuberculosis Infection Detection Market Size, by Test Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Latent Tuberculosis Infection Detection Market Size, by Offering, 2025 vs 2032 (%)
  • FIGURE 9. Global Latent Tuberculosis Infection Detection Market Size, by Offering, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Latent Tuberculosis Infection Detection Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 11. Global Latent Tuberculosis Infection Detection Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Latent Tuberculosis Infection Detection Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Latent Tuberculosis Infection Detection Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Latent Tuberculosis Infection Detection Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Latent Tuberculosis Infection Detection Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Latent Tuberculosis Infection Detection Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Latent Tuberculosis Infection Detection Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Latent Tuberculosis Infection Detection Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Latent Tuberculosis Infection Detection Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Latent Tuberculosis Infection Detection Market Segmentation & Coverage
  • TABLE 2. Global Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 4. Global Tuberculin Skin Test (TST) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Tuberculin Skin Test (TST) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Tuberculin Skin Test (TST) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Interferon-Gamma Release Assays (IGRAs) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Interferon-Gamma Release Assays (IGRAs) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Interferon-Gamma Release Assays (IGRAs) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global T-SPOT.TB Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global T-SPOT.TB Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global T-SPOT.TB Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global QuantiFERON-TB Gold (QFT) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global QuantiFERON-TB Gold (QFT) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global QuantiFERON-TB Gold (QFT) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 17. Global Software & Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Software & Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Software & Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Reagents & Consumables Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Reagents & Consumables Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Reagents & Consumables Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Assays & Kits Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Assays & Kits Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Assays & Kits Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 30. Global People Living with HIV Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global People Living with HIV Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global People Living with HIV Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Household Contacts with Pulmonary TB Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Household Contacts with Pulmonary TB Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Household Contacts with Pulmonary TB Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 37. Global Public Health Agencies & Government Bodies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Public Health Agencies & Government Bodies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Public Health Agencies & Government Bodies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Academic & Research Institutions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Academic & Research Institutions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Academic & Research Institutions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 55. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 56. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 57. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 58. Asia-Pacific Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 59. Europe Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Europe Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 61. Europe Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 62. Europe Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 63. Europe Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 64. Europe Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 65. North America Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. North America Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 67. North America Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 68. North America Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 69. North America Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 70. North America Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 71. Latin America Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Latin America Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 73. Latin America Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 74. Latin America Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 75. Latin America Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 76. Latin America Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 77. Africa Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Africa Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 79. Africa Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 80. Africa Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 81. Africa Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 82. Africa Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 83. Middle East Latent Tuberculosis Infection Detection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Middle East Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 85. Middle East Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 86. Middle East Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 87. Middle East Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 88. Middle East Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. Global Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. NATO Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. NATO Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 92. NATO Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 93. NATO Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 94. NATO Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 95. NATO Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 96. G7 Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. G7 Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 98. G7 Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 99. G7 Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 100. G7 Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 101. G7 Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 102. BRICS Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. BRICS Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 104. BRICS Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 105. BRICS Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 106. BRICS Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 107. BRICS Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 108. European Union Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. European Union Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 110. European Union Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 111. European Union Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 112. European Union Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 113. European Union Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. ASEAN Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. ASEAN Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 116. ASEAN Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 117. ASEAN Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 118. ASEAN Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 119. ASEAN Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 120. GCC Latent Tuberculosis Infection Detection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 121. GCC Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 122. GCC Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 123. GCC Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 124. GCC Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 125. GCC Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 126. Global Latent Tuberculosis Infection Detection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 127. United States Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 128. United States Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 129. United States Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 130. United States Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 131. United States Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 132. United States Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 133. China Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 134. China Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 135. China Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 136. China Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 137. China Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 138. China Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 139. Germany Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 140. Germany Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 141. Germany Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 142. Germany Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 143. Germany Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 144. Germany Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 145. Japan Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 146. Japan Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 147. Japan Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 148. Japan Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 149. Japan Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 150. Japan Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 151. India Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 152. India Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 153. India Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 154. India Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 155. India Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 156. India Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 157. United Kingdom Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 158. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 159. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 160. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 161. United Kingdom Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 162. United Kingdom Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 163. France Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 164. France Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 165. France Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 166. France Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 167. France Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 168. France Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 169. Canada Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 170. Canada Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 171. Canada Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 172. Canada Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 173. Canada Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 174. Canada Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Australia Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 176. Australia Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 177. Australia Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 178. Australia Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 179. Australia Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 180. Australia Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 181. Brazil Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 182. Brazil Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 183. Brazil Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 184. Brazil Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 185. Brazil Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 186. Brazil Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. Italy Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 188. Italy Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 189. Italy Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 190. Italy Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 191. Italy Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 192. Italy Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. Mexico Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 194. Mexico Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 195. Mexico Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 196. Mexico Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 197. Mexico Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 198. Mexico Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. South Korea Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 200. South Korea Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 201. South Korea Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 202. South Korea Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 203. South Korea Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 204. South Korea Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 205. Russia Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 206. Russia Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 207. Russia Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 208. Russia Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 209. Russia Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 210. Russia Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 211. Spain Latent Tuberculosis Infection Detection Market Size, 2017-2032 (USD Million)
  • TABLE 212. Spain Latent Tuberculosis Infection Detection Market Size, by Test Type, 2017-2032 (USD Million)
  • TABLE 213. Spain Latent Tuberculosis Infection Detection Market Size, by Interferon-Gamma Release Assays (IGRAs), 2017-2032 (USD Million)
  • TABLE 214. Spain Latent Tuberculosis Infection Detection Market Size, by Offering, 2017-2032 (USD Million)
  • TABLE 215. Spain Latent Tuberculosis Infection Detection Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. Spain Latent Tuberculosis Infection Detection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 217. Global Latent Tuberculosis Infection Detection Market Share, by Key Player, 2025
  • TABLE 218. Global Latent Tuberculosis Infection Detection Market, Key Experts